Recently, Shenzhen's "Opinions of Shenzhen Municipal People's Government on Developing and Expanding Strategic Emerging Industrial Clusters and Cultivating and Developing Future Industries" was released, and cells , genes , and synthetic biology were included in the key development directions of future industries: cultivating and growing "20+8" Industrial clusters, that is to develop 20 strategic emerging industrial clusters with advanced manufacturing as the main body, forward-looking layout of 8 major future industries, stabilize the fundamentals of the manufacturing industry, enhance the development potential of the real economy, and accelerate the construction of technology and industries with global influence Innovation Heights. By 2025, the added value of Shenzhen's strategic emerging industries will exceed 1.5 trillion yuan, becoming the main engine for promoting high-quality economic and social development.

According to the "Opinions", focus on cultivating and developing 8 major future industries , cultivating new kinetic energy, and enhancing new potential energy, including synthetic biology, blockchain, cells and genes , aerospace technology, brain science and brain-like intelligence, deep earth and deep sea, and visible light communication Computation with light, quantum information.

The relevant cell gene industry intercepts in the "Opinions" are as follows:

(1) Key sub-sectors of strategic emerging industries

17. High-end medical device industry cluster. Develop new medical imaging, life monitoring and life support, high-end implantation intervention products and other sub-fields, make breakthroughs in major equipment and key components such as high-end imaging systems, surgical robots, new in vitro diagnostic equipment, high-throughput gene sequencers, and give full play to the national As a high-performance medical device innovation center , it supports Nanshan, Longhua, Pingshan, Guangming and other districts to build agglomeration areas, and promotes the high-quality development of the high-end medical device industry.

18. Biomedical industry cluster . Support the development of innovative chemical drugs, new dosage forms and high-end preparations, modern Chinese medicine, advanced pharmaceutical equipment, and digital medicine, and promote breakthroughs in bottleneck technologies such as the research and development of new gene therapy vectors, engineering cell construction, antibody engineering optimization, and artificial intelligence-assisted drug design , and accelerate Powerlong Biopharmaceutical Innovation and Development Pilot Zone, Pingshan Biopharmaceutical Industry Accelerator Park and other projects are built to support the establishment of industrial clusters in Pingshan, Nanshan, Futian, Longgang, Guangming and Dapeng districts, and promote the biopharmaceutical industry cluster to become a new highlight of industrial development.

(2) Key development directions of future industries

3. Cells and genes . Focus on the development of cell technology, gene technology, cell and gene therapy technology, biological breeding technology and other fields, improve the cell and gene drug approval mechanism, supervision system, clinical trial incentive mechanism, application promotion mechanism, and accelerate the construction of cell and gene industry pilot areas.

On the same day, the Shenzhen Development and Reform Commission, the Shenzhen Science and Technology Innovation Commission, the Shenzhen Municipal Bureau of Industry and Information Technology, the Shenzhen Municipal Market Supervision Administration, and the Shenzhen Municipal Health Commission released the "Shenzhen Action Plan for Cultivating and Developing Biomedical Industry Clusters (2022- 2025)” (hereinafter referred to as the “Plan”).

As a supporting document for the above-mentioned "Opinions", the "Plan" proposes to promote the research and transformation of new technologies such as cells and genes.

The cell gene industry in the Action Plan is intercepted as follows:

(7) System and mechanism reform project. Give full play to the legislative power of the special economic zone and the pilot role of comprehensive authorization reform, promote the research and transformation of new technologies such as cells and genes, and conditionally use the drugs, traditional Chinese medicines and biological raw materials registered and marketed in Hong Kong and Macao in licensed medical institutions, but not yet approved in China. Policies such as circulation should be tested first. Give full play to the role of the drug review and inspection center of the State Drug Administration in the Greater Bay Area, improve the review and approval efficiency of innovative drugs in our city, and shorten the time to market. Carry out pilot work on real-world data research, and guide companies to use real-world research data to declare new drugs. (The Municipal Development and Reform Commission, the Science and Technology Innovation Commission, the Industry and Information Technology Bureau, the Health and Health Commission, the Medical Security Bureau, and the Market Supervision Bureau are responsible for the division of labor)

5. Spatial layout

The biopharmaceutical industry clusters are located in six districts: Pingshan, Nanshan, Futian, Longgang, Guangming and Dapeng. Pingshan District is positioned as a core agglomeration area, promoting the formation of frontier fields such as innovative biological drugs, high-end preparations, vaccines, cell therapy and gene therapy, promoting the transformation of traditional pharmaceutical processing to the integration of R&D and production, and creating a comprehensive “R&D + transformation + production” integration. chain ecosystem. Nanshan District is positioned as an industrial leading area, relying on universities and headquarters companies to research and develop major innovative drugs, and play a leading role in innovation. Futian District is positioned as an innovation policy exploration area. It seizes the opportunity of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone to take the lead in policy, closely connects with Hong Kong's scientific and technological resources, and combines the advantages of artificial intelligence and other industries to focus on the development of innovative drug research and development, creating a "pilot" area for biomedical policies. Longgang District is positioned as a leading area for the innovation and development of biological drugs, mainly developing and producing biological drugs such as antibody drugs, cell therapy and gene drugs . Guangming District is positioned as a technological innovation area, relying on key enterprises and innovation carriers, focusing on the research and development of biological products and technological innovation. Dapeng New Area is positioned as a pioneer area of ​​precision medicine. Relying on Shenzhen International Bio Valley, Shenzhen International Food Valley and other industrial spaces and innovative carriers, it focuses on research in cutting-edge fields such as precision medicine and inspection and testing.